Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia

Liver International

Volumn 32, Issue 3, 2012, Pages 467-475

  Kalambokis, Georgios N ^a   Mouzaki, Athanasia ^b   Rodi, Maria ^b   Tsianos, Epameinondas V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Cirrhosis; Cytokines; Endotoxin; Thrombocytopenia

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 6; RIFAXIMIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CHILD PUGH SCORE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTOXEMIA; FEMALE; HUMAN; MALE; SCORING SYSTEM; SPLEEN SIZE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CYTOKINES; ENDOTOXEMIA; ENDOTOXINS; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PLATELET COUNT; RIFAMYCINS; SPLEEN; STATISTICS, NONPARAMETRIC; THROMBOCYTOPENIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856683368     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02650.x     Document Type: Article

References (46)

1. Witters P, Freson K, Verslype C, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008; 27: 1017-29.
2. Afdhal N, McHutchinson J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48: 1000-7.
3. Qamar AA, Grace ND. Abnormal hematological indices in cirrhosis. Can J Gastroenterol 2009; 23: 441-5.
4. Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009; 7: 689-95.
5. Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003; 326: 111-6.
6. Ben-Ari Z, Cardin F, McCormick AP, Wannamethee G, Burroughs AK. Apredictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol 1999; 31: 443-50.
7. Shah SH, Haves PC, Allan PL, Nicoll J, Finlayson ND. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol 1996; 91: 2580-3.
8. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 1009-31.
9. Stockelberg D, Anderson P, Bjornsson E, Bjork S, Wadenvik H. Plasma thrombopoietin levels in liver cirrhosis and kidney failure. J Intern Med 1999; 246: 471-5.
10. Aref S, Mabed M, Selim T, Goda T, Khafagy N. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology 2004; 9: 351-6.
11. Kalambokis G, Tsianos EV. Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count. Am J Gastroenterol 2010; 105: 2705-7.
12. Gillis JC, Brogden RN. Rifaximin. A review of this antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467-84.
13. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26: 17-25.
14. Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009; 29: 992-9.
15. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral blood in patients with cirrhosis. Hepatology 1988; 8: 232-6.
16. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.
17. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
18. Garcia-Tsao G. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18: 353-72.
19. Kalambokis G, Tsianos EV. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could simple antibiotics raise blood counts? Med Hypotheses 2011; 76: 105-9.
20. Recommendations to prevent and control iron deficiency in the United States: Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 3: 1-29.
21. Larson SM, Tuell SH, Moores KD, Nelp WB. Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med 1971; 12: 123-6.
22. De Noronha R, Taylor BA, Wild G, Triger DR, Greaves M. Inter-relationships between platelet counts, platelet IgG, serum IgG, immune complexes, and severity of liver disease. Clin Lab Haematol 1991; 13: 127-35.
23. Stohlawetz P, Folman CC, von dem Borne AE, et al. Effects of endotoxemia on thrombopoiesis in man. Thromb Haemost 1999; 81: 613-7.
24. Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood 2006; 107: 637-41.
25. McGrath KM, Stuart JJ, Richards F II. Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinemic states. Br J Haematol 1979; 42: 585-91.
26. Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 1267-76.
27. Itoh H, Cicala C, Douglas GJ, Page CP. Platelet accumulation induced by bacterial endotoxin in rats. Thromb Res 1996; 83: 405-19.
28. Violi F, Ferri D, Basili S, et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995; 109: 531-9.
29. Schwager I, Jungi TW. Effect of human recombinant cytokines on the induction of macrophages procoagulant activity. Blood 1994; 83: 152-60.
30. Lee JW, Beckham C, Michel BR, Rosen H, Deeg HJ. HLA-DR-mediated signals for hematopoiesis and induction of apoptosis involve but are not limited to a nitric oxide pathway. Blood 1997; 90: 217-25.
31. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrompbopoietin response to interferon alfa-induced thrombocytopenia of patients with liver cirrhosis. Hepatology 1998; 28: 1424-9.
32. Crist SA, Elzey BD, Ludwig AT, et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megacaryocytes and platelets. Exp Hematol 2004; 32: 1073-81.
33. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: the role in inflammatory thrombocytosis. Blood 2001; 98: 2720-5.
34. Peck-Radosavljevic M, Zacheri J, Wichlas M, et al. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. Eur J Gastroenterol Hepatol 1999; 11: 151-6.
35. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 2008; 179: 333-7.
36. Salamone G, Giordano M, Trevani AS, et al. Promotion of neutrophil apoptosis by TNF-α. J Immunol 2001; 166: 3476-83.
37. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodynamic patients. Nephrol Dial Transplant 2000; 15: 1207-11.
38. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17: 39-43.
39. Davis D, Charles PJ, Potter A, et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumor necrosis factor α blockade. Br J Rheumatol 1997; 36: 950-6.
40. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-7.
41. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
42. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. Ann Intern Med 2003; 139: 186-93.
43. Runyon B, Borzio M, Young S, et al. Effective of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation and survival in an animal model of cirrhosis. Hepatology 1995; 21: 1719-24.
44. Wang T, Wang Z, Yang R. Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. Crit Rev Oncol Hematol 2011; 77: 172-83.
45. Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 437-43.
46. Pirisi M, Fabris C, Soardo G, et al. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 1994; 21: 376-80.